- Home
- MYO vs ACIU Comparison
MYO vs ACIU Comparison
Compare MYO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- ACIU
- Stock Information
- Founded
- MYO 2004
- ACIU 2003
- Country
- MYO United States
- ACIU Switzerland
- Employees
- MYO N/A
- ACIU N/A
- Industry
- MYO Industrial Specialties
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- MYO Health Care
- ACIU Health Care
- Exchange
- MYO Nasdaq
- ACIU Nasdaq
- Market Cap
- MYO 153.0M
- ACIU 173.7M
- IPO Year
- MYO 2017
- ACIU 2016
- Fundamental
- Price
- MYO $3.22
- ACIU $1.68
- Analyst Decision
- MYO Strong Buy
- ACIU Strong Buy
- Analyst Count
- MYO 4
- ACIU 2
- Target Price
- MYO $9.50
- ACIU $10.00
- AVG Volume (30 Days)
- MYO 477.7K
- ACIU 134.5K
- Earning Date
- MYO 05-07-2025
- ACIU 04-30-2025
- Dividend Yield
- MYO N/A
- ACIU N/A
- EPS Growth
- MYO N/A
- ACIU N/A
- EPS
- MYO N/A
- ACIU N/A
- Revenue
- MYO $38,628,624.00
- ACIU $32,014,254.00
- Revenue This Year
- MYO $57.44
- ACIU N/A
- Revenue Next Year
- MYO $21.76
- ACIU $676.94
- P/E Ratio
- MYO N/A
- ACIU N/A
- Revenue Growth
- MYO 97.60
- ACIU 91.20
- 52 Week Low
- MYO $2.76
- ACIU $1.43
- 52 Week High
- MYO $7.17
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- MYO 26.65
- ACIU 46.75
- Support Level
- MYO $4.65
- ACIU $1.55
- Resistance Level
- MYO $4.87
- ACIU $1.79
- Average True Range (ATR)
- MYO 0.28
- ACIU 0.10
- MACD
- MYO -0.11
- ACIU 0.03
- Stochastic Oscillator
- MYO 3.28
- ACIU 66.67
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.